Erstellt von stratec

Zealand Pharma A/s diskutieren

Zealand Pharma A/s

WKN: A0YJW7 / Name: Zealand / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

Einschätzung Buy

Rendite (%)

Kursziel 17,00

Veränderung

Endet am

Zealand Pharma vor den Zahlen steht vor einem starken Jahr 2015.

Kaufsignal.

elfe

Einschätzung Buy

Rendite (%)

Kursziel 17,00

Veränderung

Endet am

(Vom Mitglied beendet)

elfe

Einschätzung Buy

Rendite (%)

Kursziel 21,00

Veränderung

Endet am

tamam stimmt dem Sentiment von 'Buy' zu

tamam stimmt am 11.01.2018 dem Buy-Gesamtsentiment mit dem Kursziel 21.0€ zu.

I chose ZEAL due to credibility from partnerships, royalties and milestones from approved partnered drugs and associated credibility, with high upside due to large markets being targeted with wholly owned treatments.

tamam

Einschätzung Buy

Rendite (%)

Kursziel 21,41

Veränderung

Endet am

stratec stimmt der Outperform-Einschätzung der institutionellen Analysten zu

stratec stimmt am 12.06.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 21.41€ zu.

ZEAL announced updated top-line findings from its ongoing phase 3 study evaluating dasiglucagon compared with glucagon. The study met its primary and key secondary endpoints, which included immunogenicity and safety/tolerability of this glucagon mimetic. This builds on phase 2 findings showing long-lasting recovery of plasma glucose, suggesting efficacy for this agent.

If approved, this will be the first glucagon analog to be available for patients at risk for developing hypoglycemia, mainly those with Type 1 diabetes. The value proposition here is that the analog can be manufactured into a liquid formulation that is ready-made for injection by patients who are currently undergoing a hypoglycemic attack. Current preparations of glucagon have to be solubilized first, leaving room for error if patients are to deliver the drug themselves. So the fact that this analog is passing the safety and efficacy hurdles is very promising!